Glyxambi tablets are taken orally once daily, with or without food, for adults with type 2 diabetes. The fixed combination of empagliflozin and linagliptin lowers blood glucose through complementary…
Glyxambi tablets are taken orally once daily, with or without food, for adults with type 2 diabetes. The fixed combination of empagliflozin and linagliptin lowers blood glucose through complementary kidney and incretin pathways when diet and exercise alone do not provide adequate control.
The medicine is used when one treatment does not provide sufficient glucose control, or when a clinician considers two complementary mechanisms suitable for the patient’s diabetes plan.
Glyxambi is a fixed-dose combination treatment for adults diagnosed with type 2 diabetes mellitus. It combines two active substances, empagliflozin and linagliptin, to improve glycaemic control alongside an appropriate diet and physical activity [1].
The medicine is used when one treatment does not provide sufficient glucose control, or when a clinician considers two complementary mechanisms suitable for the patient’s diabetes plan. Glyxambi is not intended for type 1 diabetes or for the emergency treatment of diabetic ketoacidosis.
Glyxambi may be prescribed for adults with type 2 diabetes whose blood glucose remains above the individual treatment target despite lifestyle measures and prescribed diabetes therapy. The choice depends on kidney function, previous treatments, cardiovascular history, hydration status, and the risk of hypoglycaemia.
Kidney function deserves attention before treatment and during follow-up. Empagliflozin’s glucose-lowering effect depends on renal filtration, so the clinical benefit can change as kidney function changes.
Glyxambi is taken as an oral tablet once daily, at approximately the same time each day. It may be taken with or without food. The prescribed strength depends on the previous empagliflozin and linagliptin regimen, kidney function, glycaemic response, and other diabetes medicines.
Dosing differs between strengths and between users, so there is no single amount that suits everyone. A prescriber determines the strength and whether a fixed combination is appropriate.
Do not stop empagliflozin during illness without receiving specific medical instructions. Fever, vomiting, diarrhoea, reduced food intake, or prolonged fasting can increase the risk of ketoacidosis, even when blood glucose is not extremely high.
Linagliptin has been associated with pancreatitis in post-marketing reports.
Persistent severe abdominal pain that may radiate to the back, with or without vomiting, requires urgent evaluation.
Empagliflozin can contribute to dehydration and hypotension. Extra caution is needed in older adults, people taking loop or thiazide diuretics, and those with low blood pressure or limited fluid intake.
This treatment is NOT for you if you have type 1 diabetes, current diabetic ketoacidosis, severe dehydration, or a contraindication to either active substance.
The most relevant adverse effects relate to glucose passing into the urine, fluid loss, and the effect of other diabetes medicines. Clinical trial and regulatory information identifies urinary tract infection, genital fungal infection, increased urination, thirst, dehydration, and hypoglycaemia during combination treatment as important considerations [3].
Common or clinically relevant reactions may include:
Hypoglycaemia is more likely when Glyxambi is used with insulin, glipizide, glyburide, or glimepiride. Warning signs include sweating, shaking, hunger, palpitations, confusion, blurred vision, and unusual weakness.
Urgent medical assessment is needed for severe abdominal pain, nausea, vomiting, deep or rapid breathing, marked drowsiness, or confusion. These symptoms can indicate diabetic ketoacidosis. The condition can occur with SGLT2 inhibitors even when the blood glucose reading is not dramatically elevated.
Serious urinary or genital infection is uncommon but requires prompt treatment. Fever, flank pain, blood in the urine, severe genital pain, swelling, or rapidly worsening redness should not be ignored.
Genital symptoms should be reported early. Waiting several days can allow a treatable fungal infection to become painful and recurrent.
Glyxambi works through two different pathways. Empagliflozin increases urinary glucose excretion, while linagliptin strengthens the body’s glucose-dependent insulin response.
| Active substance | Pharmacological class | Main action |
|---|---|---|
| Empagliflozin | SGLT2 inhibitor | Reduces kidney reabsorption of filtered glucose |
| Linagliptin | DPP-4 inhibitor | Increases incretin activity, supporting insulin release and lowering glucagon |
The kidneys filter glucose from the blood and normally reabsorb much of it through sodium-glucose cotransporter 2, known as SGLT2. Empagliflozin blocks this transporter, allowing more glucose to leave the body in urine.
This mechanism can also increase urinary sodium and fluid loss. For some patients, that contributes to lower blood pressure and reduced fluid load, although dizziness, dehydration, and low blood pressure can occur when fluid intake is inadequate or when other diuretics are used.
Empagliflozin does not stimulate insulin release directly. Its glucose-lowering action therefore remains partly independent of pancreatic beta-cell function, although the risk of ketoacidosis still requires clinical attention.
Linagliptin inhibits the enzyme dipeptidyl peptidase-4, or DPP-4. This prolongs the activity of incretin hormones released after meals. The result is increased insulin release when blood glucose is elevated and reduced glucagon secretion.
Glucagon normally signals the liver to release glucose. Lower glucagon activity reduces hepatic glucose output and limits the release of stored glucose from glycogen. Because linagliptin’s insulin effect is glucose-dependent, it has a lower intrinsic risk of hypoglycaemia than medicines that force insulin release regardless of the blood glucose level [2].
Several practical errors can reduce treatment benefit or increase risk:
A further mistake is judging the medicine only by a single glucose reading. HbA1c, fasting values, post-meal readings, kidney function, blood pressure, and symptoms provide a more useful picture.
Glyxambi differs from metformin because it combines an SGLT2 inhibitor with a DPP-4 inhibitor rather than reducing liver glucose production as its primary action. It differs from insulin because it does not replace insulin directly. Insulin remains essential for people with type 1 diabetes and may be required in advanced insulin deficiency.
A fixed combination can reduce the number of separate tablets in a treatment plan.
The limitation is that it also combines the precautions of both active substances, including urinary glucose-related infections, dehydration, ketoacidosis risk, and rare hypersensitivity reactions.
In clinical practice, doctors often view Glyxambi as a treatment for adults who need two complementary glucose-lowering mechanisms in one daily tablet. The choice is strongest when the patient can maintain hydration, recognise warning symptoms, and attend kidney-function monitoring.
A clinician will usually assess HbA1c, estimated glomerular filtration rate, blood pressure, fluid status, previous genital or urinary infections, and the complete diabetes regimen. The same tablet may be reasonable for one patient and unsuitable for another because kidney function, insulin use, and cardiovascular status change the balance of benefits and risks.
The main limitation is that Glyxambi does not remove the need for diet, activity, glucose monitoring, or follow-up. It also does not replace insulin in type 1 diabetes or treat ketoacidosis.
Glyxambi is taken once daily and may be taken with or without food. Taking it in the morning can be practical because empagliflozin may increase urination, though the best time depends on the person’s routine and prescribed plan. The 2024 EMA describes once-daily administration, while the 2024 HPRA emphasises using medicines according to the approved product information. Avoid taking an additional tablet if the timing becomes uncertain.
Empagliflozin can begin increasing urinary glucose excretion after treatment starts, while the full assessment of glucose control usually relies on repeated readings and HbA1c rather than symptoms alone. Linagliptin also contributes to glucose control over continued treatment rather than producing a reliable immediate sensation. Clinical studies reviewed by the 2024 EMA assess response over weeks, with HbA1c providing the main measure of sustained effect. A person may feel no different even when the medicine is lowering glucose.
Glyxambi combines an SGLT2 inhibitor with a DPP-4 inhibitor. Empagliflozin promotes renal glucose excretion, while linagliptin enhances incretin activity and reduces glucagon release. Metformin primarily reduces hepatic glucose production, and insulin directly replaces or supplements insulin activity. The 2020 WHO describes these mechanisms as distinct tools within type 2 diabetes care, with treatment selection based on individual clinical factors.
Glyxambi is intended for adults with type 2 diabetes and is not routinely used in people under 18. Paediatric diabetes requires a treatment plan based on the child’s diagnosis, growth, insulin needs, kidney function, and specialist assessment. The 2024 EMA product information does not establish Glyxambi as a routine paediatric treatment. A child or teenager should not receive an adult’s tablets.
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
Based on 3 reviews
Took the once-daily tablet alongside his existing diabetes routine for several months. He noticed more frequent urination during the first week and had to plan fluids more carefully, but his glucose readings became steadier after his treatment review.
Several months 4 Nov 2026Used the combination with insulin and experienced two episodes of low blood sugar after his insulin dose was not adjusted. Once the regimen was reviewed, the readings improved, although he remained cautious about taking the tablet during stomach illnesses.
7 Oct 2026Reported better morning glucose readings after changing to the combination. He developed genital irritation during the first month, received treatment, and later found the medicine easier to manage after learning the early warning signs.
The first month 21 Oct 2026
